Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Infect Dis ; 12(6): 573-7, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18539496

RESUMEN

Brucellosis is a systemic disease and may affect many organ systems. However, musculoskeletal involvement represents 10-85% of the focal complications. Involvement of the spine is one of the most common localized forms of human brucellosis, especially in elderly patients. It is a destructive disease that requires a correct and early diagnosis, and immediate treatment. However, controversy remains over the optimal duration and antimicrobial regimen required for the treatment of spinal brucellosis. Relapses and sequelae are still reported. In recent years, in order to improve outcomes, alternative regimens have been investigated. However, the classical regimen (doxycycline, 100mg twice daily, for at least 12 weeks combined with streptomycin, 1g daily, for the first 2 or 3 weeks) remains the first choice of antibiotic therapy. Alternative therapies (rifampin, fluoroquinolones, co-trimoxazole) should be considered when adverse reactions or contraindications to the above drugs (ototoxicity, nephrotoxicity, pregnancy, etc.) are reported.


Asunto(s)
Antibacterianos/uso terapéutico , Brucelosis/tratamiento farmacológico , Brucelosis/cirugía , Enfermedades de la Columna Vertebral/tratamiento farmacológico , Enfermedades de la Columna Vertebral/cirugía , Brucelosis/epidemiología , Brucelosis/microbiología , Humanos , Incidencia , Enfermedades de la Columna Vertebral/epidemiología , Enfermedades de la Columna Vertebral/microbiología , Columna Vertebral/microbiología , Columna Vertebral/patología , Espondilitis/tratamiento farmacológico , Espondilitis/microbiología , Espondilitis/patología , Espondilitis/cirugía
2.
Scand J Infect Dis ; 38(5): 335-40, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16709534

RESUMEN

Acinetobacter baumannii is a significant pathogen of bloodstream infections in hospital patients that frequently causes single clone outbreaks. We aimed to evaluate the genetic relatedness and antimicrobial susceptibility of Acinetobacter spp. bloodstream isolates, in order to obtain insight into their cross-transmission. This prospective study was conducted at the Erciyes University Hospital. During a 1-y period, all patients with nosocomial BSI caused by Acinetobacter spp. were included in the study. All data with regard to the patients, underlying diseases and risk factors for BSI and the severity of disease were collected. Blood culture isolates of Acinetobacter spp. were identified according to their morphology and biochemical reactions. The antimicrobial susceptibility was determined using the Kirby-Bauer disk diffusion test according to the NCCLS; the genetic relatedness of isolates was determined by RAPD-PCR analysis and pulsed-field gel electrophoresis (PFGE). 41 patients acquired a nosocomial bloodstream infection caused by A. baumanii during this period. 88% of these infections (36 of 41) occurred while the patients were treated in the intensive care unit. Nearly 80% of the isolates belonged to 3 genotypes, suggesting cross-transmission in ICU settings where infection control practices are poor. All Acinetobacter isolates were multidrug-resistant and the crude mortality of patients infected with A. baumanii was 80.5%. We concluded that the genetic relatedness of Acinetobacter spp. causing BSI was very high, indicating cross-transmission within the ICU setting. Essential components of an infection control programme to prevent nosocomial transmission of A. baumannii are early detection of colonized patients, followed by strict attention to standard precautions and contact isolation.


Asunto(s)
Infecciones por Acinetobacter/microbiología , Acinetobacter baumannii/genética , Antibacterianos/uso terapéutico , Bacteriemia/microbiología , Infección Hospitalaria/microbiología , APACHE , Infecciones por Acinetobacter/tratamiento farmacológico , Infecciones por Acinetobacter/epidemiología , Infecciones por Acinetobacter/transmisión , Acinetobacter baumannii/clasificación , Acinetobacter baumannii/efectos de los fármacos , Acinetobacter baumannii/aislamiento & purificación , Bacteriemia/tratamiento farmacológico , Bacteriemia/epidemiología , Bacteriemia/transmisión , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/epidemiología , Infección Hospitalaria/transmisión , Brotes de Enfermedades , Farmacorresistencia Bacteriana Múltiple , Electroforesis en Gel de Campo Pulsado , Femenino , Genotipo , Hospitales Universitarios , Humanos , Unidades de Cuidados Intensivos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Prospectivos , Técnica del ADN Polimorfo Amplificado Aleatorio , Turquía/epidemiología
3.
BMC Infect Dis ; 6: 72, 2006 Apr 11.
Artículo en Inglés | MEDLINE | ID: mdl-16606473

RESUMEN

BACKGROUND: The optimal treatment regimen and duration of the therapy is still controversial in spinal brucellosis. The aim of this study is to compare the efficacy, adverse drug reactions, complications and cost of ciprofloxacin plus rifampicin versus doxycycline plus streptomycin in the treatment of spinal brucellosis. METHODS: The patients diagnosed as spinal brucellosis between January 2002 to December 2004 were enrolled into the study. Patients were enrolled into the two antimicrobial therapy groups (doxycycline plus streptomycin vs. ciprofloxacin plus rifampicin) consecutively. For the cost analysis of the two regimens, only the cost of antibiotic therapy was analysed for each patient. RESULTS: During the study period, 31 patients with spinal brucellosis were enrolled into the two antimicrobial therapy groups. Fifteen patients were included in doxycycline plus streptomycin group and 16 patients were included in ciprofloxacin plus rifampicin group. Forty-two levels of spinal column were involved in 31 patients. The most common affected site was lumbar spine (n = 32, 76%) and involvement level was not different in two groups. Despite the disadvantages (older age, more prevalent operation and abscess formation before the therapy) of the patients in the ciprofloxacin plus rifampicin group, the duration of the therapy (median 12 weeks in both groups) and clinical response were not different from the doxycycline plus streptomycin. The cost of ciprofloxacin plus rifampicin therapy was 1.2 fold higher than the cost of doxycycline plus streptomycin therapy. CONCLUSION: Classical regimen (doxycycline plus streptomycin), with the appropriate duration (at least 12 weeks), is still the first line antibiotics and alternative therapies should be considered when adverse drug reactions were observed.


Asunto(s)
Brucelosis/tratamiento farmacológico , Ciprofloxacina/uso terapéutico , Doxiciclina/uso terapéutico , Rifampin/uso terapéutico , Estreptomicina/uso terapéutico , Antibacterianos/economía , Antibacterianos/uso terapéutico , Ciprofloxacina/administración & dosificación , Ciprofloxacina/economía , Doxiciclina/administración & dosificación , Doxiciclina/economía , Quimioterapia Combinada , Humanos , Rifampin/administración & dosificación , Rifampin/economía , Columna Vertebral/microbiología , Columna Vertebral/patología , Espondilitis/tratamiento farmacológico , Espondilitis/microbiología , Espondilitis/patología , Estreptomicina/administración & dosificación , Estreptomicina/economía
4.
Endocr J ; 52(2): 183-8, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15863945

RESUMEN

The aim of the study was to investigate the hypothalamo-pituitary-adrenal (HPA) axis by ACTH stimulation test and the changes in adrenal size in acute brucellosis before and after therapy in a prospective study. Sixteen patients with acute brucellosis and 15 healthy subjects were included in the study during the last two years. Cortisol levels were assessed before, 30 and 60 minutes after ACTH (250 microg i.v.) injection and the size of the adrenals was measured in both groups. Mean basal cortisol levels in the patients before the therapy and after the therapy were 22.1 +/- 6.9 microg/dL and 11.3 +/- 6.0 microg/dL, respectively. The difference was statistically significant (p<0.001). There was also statistically significant difference for basal cortisol levels between the healthy subjects (12.2 +/- 4.6 microg/dL) and the patients before the therapy (p<0.001). Peak cortisol responses to ACTH were higher before the therapy in the patients with acute brucellosis (39.3 +/- 10.7 microg/dL) than in the healthy subjects (30.4 +/- 4.8 microg/dL, p = 0.014). However, there was no significant difference for peak cortisol levels in the patients before and after the therapy (32.7 +/- 8.0 microg/dL). Mean basal cortisol levels and peak cortisol responses to ACTH between the patients after the therapy and the healthy controls were similar. Both the maximum width of the adrenal glands and the width of the adrenal limbs were significantly greater before the therapy compared to healthy subjects and post-treatment period. We concluded that the HPA axis is activated and the adrenal glands are enlarged in acute brucellosis, which is reduced after appropriate therapy.


Asunto(s)
Glándulas Suprarrenales/patología , Glándulas Suprarrenales/fisiopatología , Brucelosis/patología , Brucelosis/fisiopatología , Hipotálamo/fisiopatología , Hipófisis/fisiopatología , Enfermedad Aguda , Adolescente , Glándulas Suprarrenales/diagnóstico por imagen , Hormona Adrenocorticotrópica , Adulto , Anciano , Brucelosis/tratamiento farmacológico , Femenino , Humanos , Hidrocortisona/sangre , Cinética , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Tomografía Computarizada por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA